Delivery Order SPE2DB22D9207-SPE2DB24FH5DS

Award Date 8/1/24
Potential Completion Date 8/22/24
Potential Value $15K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $15,358.74 and covers the delivery of Kadcyla 100 mg vials, a specialty oncology medication, with a completion date of August 15, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $15,358.74, is for the supply of Kadcyla 100 mg vials, an oncology drug, with a period of performance through May 24, 2024. This order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler located in Park Ridge, Illinois. The $15,358.74 contract is for the delivery of Kadcyla 100 mg vials, a specialized oncology medication, by January 14, 2025. This order is placed under DMS Pharmaceutical Group's existing $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which enables the agency to issue...
This is a Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $23,531.70, is for the delivery of Kadcyla 100 mg vials, a specialized oncology medication. DMS Pharmaceutical Group holds a larger single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,358.74 contract is for the supply of Kadcyla 100 mg vials, with a period of performance through August 28, 2024. DMS Pharmaceutical Group holds a large single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued up to $499,999,999, which allows the...
This is a Firm Fixed Price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,358.74 contract is for the supply of Kadcyla 100 mg vials, an oncology drug, with a period of performance through July 19, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with DLA under the SPE2DB program, which allows the agency...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $22,624.14, is for the delivery of Kadcyla 160 mg vials, a specialty oncology medication. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) with DMS Pharmaceutical Group Inc. under the DLA's SPE2DB program, which allows for the issuance...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $13,327.42 and covers the delivery of Kadcyla 160 mg vials, a specialty oncology drug, with a period of performance through August 6, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $5,731.36 firm fixed-price contract is for the supply of 160 mg vials of the cancer drug Kadcyla. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a comprehensive range of...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $20,478.24, is for the delivery of Kadcyla 100 mg vials. DMS Pharmaceutical Group holds a significant Indefinite Delivery Contract (IDC) with the DLA, valued at up to $499,999,999, that runs through December 31, 2025. This single-award vehicle allows the...
  • SPE2DB22D9207
    Indefinite Delivery Contract
  • SPE2DB22D9207-SPE2DB24FH5DS
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $15,358.74, is for the delivery of Kadcyla 100 mg vials, a specialty oncology drug, with a performance period that runs through August 22, 2024.

DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999 and expiring on December 31, 2025. This IDC allows the DLA to issue firm fixed-price delivery orders for a wide range of pharmaceutical items to support the recurring medical supply needs of military health facilities worldwide. Through this vehicle, DMS Pharmaceutical Group provides both routine and critical medications, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to military healthcare facilities.

The contract does not have a set-aside designation, and DMS Pharmaceutical Group leverages its status as a woman-owned small business to secure these direct awards to support the Department of Defense's pharmaceutical supply chain requirements.

Generated 10/31/24, 9:42 AM